By: Benzinga
UPDATE: Canaccord Upgrades Vertex Pharmaceuticals to Buy Following Release of VX-661 Data
In a report published Friday, Canaccord Genuity analyst Salveen Richter upgraded the rating on Vertex Pharmaceuticals (NASDAQ: VRTX ) from Hold to Buy, and raised the price target from $55.00 to $96.00. In the report, Richter noted, “Last night, VRTX released P2 data from VX-661 monotherapy + combination therapy in
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here